SCHEMBL10269334

SCHEMBL10269334

O=C(Nc1ccc2cn[nH]c2c1)c1cc(-c2cc3ccccc3s2)c2[nH]ncc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.51
CLK2 P49760 1/20 0.51
DYRK1A Q13627 1/20 0.51
SRPK1 Q96SB4 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HPGD P15428 2/20 0.49
MAPKAPK2 P49137 2/20 0.48
ALDH1A1 P00352 1/20 0.48
JAK2 O60674 1/20 0.47
MAOB P27338 5/20 0.47
CFTR P13569 1/20 0.45
DDR2 Q16832 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10269329 0.92 NPC1 (0.58) MAP4K4CLK2DYRK1ACLK4RAB9A
SCHEMBL10269197 0.89 MAPKAPK2 (0.52) MAP4K4CLK2DYRK1ASRPK1CLK4
SCHEMBL10269598 0.89 MAPKAPK2 (0.46) MAP4K4CLK2DYRK1ASRPK1CLK4
SCHEMBL10269605 0.87 MAPKAPK2 (0.49) MAP4K4CLK2DYRK1ASRPK1CLK4
SCHEMBL10269600 0.87 MAPKAPK2 (0.49) MAP4K4CLK2DYRK1ASRPK1CLK4
SCHEMBL10269333 0.86 SMN1; SMN2 (0.48) MAP4K4CLK2DYRK1ASRPK1CLK4
SCHEMBL10269035 0.86 MAPKAPK2 (0.49) MAP4K4CLK2DYRK1ASRPK1CLK4
SCHEMBL10269335 0.86 MAPKAPK2 (0.48) MAP4K4CLK2DYRK1ASRPK1CLK4
SCHEMBL10269142 0.86 MAPKAPK2 (0.47) MAP4K4CLK2DYRK1ASRPK1CLK4
SCHEMBL10213041 0.85 MAPKAPK2 (0.49) MAP4K4CLK2DYRK1ASRPK1CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 MAP4K4 2140/4885CLK2 2684/4885DYRK1A 3722/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 MAP4K4 2140/4885CLK2 2684/4885DYRK1A 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.